Skip to main content
OpenTrials
Completed

NCT Number: NCT01398904

Attentional Bias in Body Dysmorphic Disorder

Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Body Dysmorphic Disorders Mental Disorders Somatoform Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for BDD and healthy control participants:

  • males and females 18 years of age or older
  • sufficient fluency of English to understand study staff, procedures, and questionnaires
  • ability to provide informed consent

Inclusion for BDD participants only;

  • primary diagnosis of Diagnostic and Statistical Manual 4th Edition (DSM-IV-TR) BDD
  • BDD Yale-Brown Obsessive Compulsive Disorder score (Y-BOCS) of > 20
  • primary facial/head concern

Exclusion criteria

  • Major medical or neurological conditions
  • schizophrenia, schizoaffective disorder, or any other current lifetime DSM-IV psychotic disorder that is not attributable to delusional BDD
  • current suicidality
  • current homicidality

Exclusion criteria

for healthy controls:

  • Any current Axis I psychiatric illness
  • history of BDD

Treatment and study plan

Primary outcomes

  1. Attention Pattern

    Time frame: Day 2

    Gaze tracking via an Eyelink II eye tracker will determine perception of visual information.

Secondary outcomes

  1. Subjective Units of Distress Scale (SUDS)

    Time frame: Day 2

    Participants will provide a distress score based on the facial images observed.

  2. Facial Attractiveness

    Time frame: Day 2

    Using a 9-point Likert scale, participants will rate the perceived most attractive and unattractive feature of their own and the control face.

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Registry information

Acronym: VAB

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jul 21, 2011
Registry last updated
Dec 3, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.